Continuous manufacturing is transforming pharmaceutical production, shifting from large-scale batch processing to small-scale modular systems. The COVID-19 pandemic highlighted the need for small-scale manufacturing near raw material sources (Sharma et al., 2020). Advancements in small-scale development have allowed for the integration of various unit operations like reaction, extraction, and crystallization for purification and polymorphic control, offering improved efficiency, safety, adaptability to the industry in the form of end-to-end manufacturing (Nagy et al., 2021). This work explores modular manufacturing for chemotherapy drugs with process intensification. The mini pharm setup that was developed, implemented, and demonstrated on high-value, low-demand drugs, Lomustine and Imatinib Mesylate.
Lomustine, a chemotherapy drug, affected by monopoly induced price gauging, was successfully manufactured in the mini-pharm platform through process intensification. A two-step synthesis and solvent switch distillation were utilized. Gas chromatography-mass spectrometer was used to analyze the distillation samples. Lomustine was purified via continuous combined cooling and antisolvent crystallization.
For Imatinib Mesylate, three key studies were conducted: solvent screening and solubility, precipitation reactions, and polymorphic crystallization. Solubility experiments identified a suitable solvent. Precipitation reactions produced the metastable form of Imatinib Mesylate. Polymorphic transformation experiments to isolate the stable form of the compound. Stable Imatinib Mesylate was produced via continuous cooling crystallization and verified with analytical technology tools and powder X-ray diffraction.
This study demonstrates the feasibility and advantages of small-scale modular manufacturing for Lomustine and Imatinib Mesylate, highlighting end-to-end continuous manufacturing improvements, even for hazardous anti-cancer drugs. It offers valuable insights for advancing pharmaceutical manufacturing through process intensification.
Keywords: End-to-end drug manufacturing, polymorphism, modular manufacturing
References
- Grover, J. Mackey, G. Pruneda, E. Zenk, and Z. K. Nagy, “Continuous Extraction of 2-Chloroethyl isocyanate for Lomustine Intermediate Purification.”, 2023.
- Sundarkumar, W. Wang, M. Mills, S. W. Oh, Z. Nagy, and G. Reklaitis, “Developing a Modular Continuous Drug Product Manufacturing System with Real Time Quality Assurance for Producing Pharmaceutical Mini-Tablets,” J Pharm Sci, 2023, doi: 10.1016/j.xphs.2023.09.024.
- Sharma, P. Gupta, and R. Jha, “COVID-19: Impact on Health Supply Chain and Lessons to Be Learnt,” Journal of Health Management, vol. 22, no. 2, pp. 248–261, Jun. 2020, doi: 10.1177/0972063420935653.
- Nagy et al., “Dynamic flowsheet model development and digital design of continuous pharmaceutical manufacturing with dissolution modeling of the final product,” Chemical Engineering Journal, vol. 419, no. March, 2021, doi: 10.1016/j.cej.2021.129947.
- Casas-Orozco et al., “Techno-economic analysis of dynamic, end-to-end optimal pharmaceutical campaign manufacturing using PharmaPy,” AIChE Journal, vol. 69, no. 9, Sep. 2023, doi: 10.1002/aic.18142.
- Jaman, T. J. P. Sobreira, A. Mufti, C. R. Ferreira, R. G. Cooks, and D. H. Thompson, “Rapid On-Demand Synthesis of Lomustine under Continuous Flow Conditions,” Org Process Res Dev, vol. 23, no. 3, pp. 334–341, 2019, doi: 10.1021/acs.oprd.8b00387.
